The latest price target for ADC Therapeutics (NYSE:ADCT) was reported by Cantor Fitzgerald on March 7, 2025. The analyst firm set a price target for $0.00 expecting ADCT to fall to within 12 months (a possible -100.00% downside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for ADC Therapeutics (NYSE:ADCT) was provided by Cantor Fitzgerald, and ADC Therapeutics reiterated their overweight rating.

The last upgrade for ADC Therapeutics SA happened on August 10, 2023 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for ADC Therapeutics SA.

The last downgrade for ADC Therapeutics SA happened on November 9, 2023 when TD Cowen changed their price target from N/A to N/A for ADC Therapeutics SA.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.

While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $0.00. The current price ADC Therapeutics (ADCT) is trading at is $1.58, which is out of the analyst’s predicted range.